Sage Group reports strong growth in Q4'24 and Q1'25, driven by Sage Intacct and AI innovation. Read why SGGEF stock is a Hold ...

On Wednesday, H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company ...

Sage Accounting is an established financial services provider offering comprehensive accounting solutions beyond simply balancing the books. But here’s the catch: it comes at a price.

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE ...

JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating on the name. The price target accounts for peaks sales ...

Royal Bank of Canada raised shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective on the stock in a report on Thursday ...

The Sage Group plc (LON:SGE – Get Free Report)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,169.95 ($15.06) and ...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ...